Home Brain Cancer Brain tumors impact normally helpful cells Astrocytes encasing gliomas exhibit different molecular signatures based on their proximity to the cancer cells. Brain CancerElectrophysiologyFeaturedNeurologyNeuroscienceOpen Neuroscience Articles·April 6, 2020The same brain cells designed to stop brain damage fail to support healthy neurons when a cancer grows. New research, led by Stefanie Robel and Harald Sontheimer at the Fralin Biomedical Research Institute at VTC, reveals how gliomas alter astrocytes, a cell type that helps protect neurons and is crucial to preventing seizures. The image is credited to Virginia Tech. Summary: Glioma brain tumors alter the function of astrocytes, possibly contributing to seizures many brain cancer patients experience. Astrocytes encasing gliomas exhibit different molecular signatures based on their proximity to the cancer cells. Those directly touching the cancer cells become elongated and swollen, mimicking the astrocyte’s response to other epilepsy-related brain injuries. Source: Virginia Tech When the brain gets injured, star-shaped brain cells called astrocytes come to the rescue. In the case of glioma – the most common type of primary brain tumor – this protective action comes at a price. A new study published in Neurochemistry International reveals that gliomas alter astrocyte function, which normally prevents the brain from being flooded with excess excitatory chemicals. This could contribute to the seizures experienced by many brain cancer patients. “Seizures are a serious and debilitating comorbidity that affect most patients with primary brain tumors. Unfortunately, epilepsy dramatically reduces quality of life, and our current anti-epileptic drugs are not effective for all patients,” said Stefanie Robel, an assistant professor at the Fralin Biomedical Research Institute at VTC and the study’s co-senior author. “My lab is looking for other cellular and molecular targets that contribute to seizures resulting from gliomas, and so far, what we’re finding is that the scar-forming astrocytes that surround the tumor play an important role.” Gliomas are competitive, fast-growing tumors that – just like all other living cells – need an energy source to survive. Composed primarily of glia cells, gliomas take over the brain’s microvasculature, syphoning off a fresh supply of nutrients from other healthy cells. The tumors also release toxic levels of glutamate, an excitatory neurotransmitter, which can kill off the brain’s densely packed healthy neurons, making space for the cancer to grow. An abundance of glutamate can also cause more neurons to become electrically active, which can result in seizures. Astrocytes swiftly scar the tumor to protect the brain from further damage – but this comes at a price. “Under ordinary circumstances, you’d expect astrocytes to buffer any additional glutamate. Part of their job is to maintain balanced, homeostatic conditions for neurons by removing excess glutamate and potassium,” said Robel, who is also an assistant professor in Virginia Tech’s School of Neuroscience and the Virginia Tech Carilion School of Medicine. “Like micro vacuum cleaners, they tidy up neurotransmitters and ions floating amid brain cells.” But the astrocytes encasing gliomas exhibited different molecular signatures based on their proximity to the cancer. The cells directly touching the tumor were elongated and swollen, mimicking the response to other brain injuries associated with epilepsy, such as stroke or physical trauma. Electrophysiology and staining experiments revealed the stretched cells also lacked proper localization or function of proteins needed to carry potassium and glutamate inside an astrocyte. The cells had also lost a vital enzymatic process that converts glutamate into glutamine, a molecule that neurons use to suppress activity. Under these conditions, the brain’s delicate balance of excitation and inhibition tips, and problems arise. Toxic levels of glutamate emitted from the tumor, exacerbated by the astrocytes dysfunctional state, destroy healthy neurons. Previous studies led by Sontheimer showed that the fluid suspended between brain cells reaches harmful levels of excitability – enough to spark a seizure. After the first seizure, the circuits involved are preferentially strengthened, making future episodes even more likely. “A tumor is a dynamic, living tissue that sends and receives chemical signals to surrounding glial cells and neurons, influencing their behavior,” Robel said. “What we’re seeing is that these very fine changes in astrocyte function and morphology in glioma response could have a very big impact for the patient.” As more research about astrocytic response to injury, disease, and cancer is published, Robel hopes that larger patterns will emerge. “If we can understand what astrocytes do in the context of glioma, brain trauma, or even autism, maybe these overarching biological patterns will help us identify new diagnostics, therapies, and treatments to help patients suffering from a wide range of diseases,” Robel said. The study’s co-senior author was Harald Sontheimer, a professor; Commonwealth Eminent Scholar in Cancer Research, and director of the Center for Glial Biology in Health, Disease, and Cancer at the Fralin Biomedical Research Institute; and executive director of Virginia Tech’s School of Neuroscience. The lead co-authors, Carmen Muñoz-Ballester, a postdoctoral associate in Robel’s laboratory at the Fralin Biomedical Research Institute, and Susan Campbell, an assistant professor in the Virginia Tech College of Agriculture and Life Sciences, were both involved in the study’s methodology, analysis, investigation, and writing.See alsoFeaturedNeurosciencePsychology·January 28, 2020Research offers promise for treating schizophrenia Funding: This research was funded by the National Institutes of Health, the Epilepsy Foundation, and the American Brain Tumor Association. About this neuroscience research article Source: Virginia Tech Media Contacts: Whitney Slightham – Virginia Tech Image Source: The image is credited to Virginia Tech. Original Research: Open access “Potassium and glutamate transport is impaired in scar-forming tumor-associated astrocytes”. Stefanie Robel et al. Neurochemistry International doi:10.1016/j.neuint.2019.104628. Abstract Potassium and glutamate transport is impaired in scar-forming tumor-associated astrocytes Unprovoked recurrent seizures are a serious comorbidity affecting most patients who suffer from glioma, a primary brain tumor composed of malignant glial cells. Cellular mechanisms contributing to the development of recurrent spontaneous seizures include the release of the excitatory neurotransmitter glutamate from glioma into extracellular space. Under physiological conditions, astrocytes express two high affinity glutamate transporters, Glt-1 and Glast, which are responsible for the removal of excess extracellular glutamate. In the context of neurological disease or brain injury, astrocytes become reactive which can negatively affect neuronal function, causing hyperexcitability and/or death. Using electrophysiology, immunohistochemistry, fluorescent in situ hybridization, and Western blot analysis in different orthotopic xenograft and allograft models of human and mouse gliomas, we find that peritumoral astrocytes exhibit astrocyte scar formation characterized by proliferation, cellular hypertrophy, process elongation, and increased GFAP and pSTAT3. Overall, peritumoral reactive astrocytes show a significant reduction in glutamate and potassium uptake, as well as decreased glutamine synthetase activity. A subset of peritumoral astrocytes displayed a depolarized resting membrane potential, further contributing to reduced potassium and glutamate homeostasis. These changes may contribute to the propagation of peritumoral neuronal hyperexcitability and excitotoxic death. Feel Free To Share This Brain Cancer News. Join our Newsletter I agree to have my personal information transferred to AWeber for Neuroscience Newsletter ( more information ) Sign up to receive the latest neuroscience headlines and summaries sent to your email daily from NeuroscienceNews.comWe hate spam and only use your email to contact you about newsletters. We do not sell email addresses. You can cancel your subscription any time.